Abstract:Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of aberrant cells. Thus, RCD pathways represented by apoptosis have increased in importance as a target for the development of cancer medications in recent years. However, because tumor cells show avoidance to apoptosis, which causes treatment resistance and recurrence, numerous studies have been devoted to alternative cancer cell mortality processes, namely necroptosis, pyroptosis, ferroptosis, and cuproptosis; these RCD modalities have been extensively studied and shown to be crucial to cancer therapy effectiveness. Furthermore, evidence suggests that tumor cells undergoing regulated death may alter the immunogenicity of the tumor microenvironment (TME) to some extent, rendering it more suitable for inhibiting cancer progression and metastasis. In addition, other types of cells and components in the TME undergo the abovementioned forms of death and induce immune attacks on tumor cells, resulting in enhanced antitumor responses. Hence, this review discusses the molecular processes and features of necroptosis, pyroptosis, ferroptosis, and cuproptosis and the effects of these novel RCD modalities on tumor cell proliferation and cancer metastasis. Importantly, it introduces the complex effects of novel forms of tumor cell death on the TME and the regulated death of other cells in the TME that affect tumor biology. It also summarizes the potential agents and nanoparticles that induce or inhibit novel RCD pathways and their therapeutic effects on cancer based on evidence from in vivo and in vitro studies and reports clinical trials in which RCD inducers have been evaluated as treatments for cancer patients. Lastly, we also summarized the impact of modulating the RCD processes on cancer drug resistance and the advantages of adding RCD modulators to cancer treatment over conventional treatments.

Advancements in programmed cell death research in antitumor therapy: a comprehensive overview

Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets

Research progress on morphology and mechanism of programmed cell death

Programmed Cell Death Tunes Tumor Immunity

Programmed Cell Death, from a Cancer Perspective: An Overview

Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives

Cell death pathways: molecular mechanisms and therapeutic targets for cancer

Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects

Advances in tumor nanotechnology: theragnostic implications in tumors via targeting regulated cell death

Programmed Cell Death: Complex Regulatory Networks in Cardiovascular Disease

Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review

Gene Expression Regulation and the Signal Transduction of Programmed Cell Death

Anti-apoptosis and cell survival: A review

Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression

Non-Canonical Programmed Cell Death in Colon Cancer

Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy

Interrelation between Programmed Cell Death and Immunogenic Cell Death: Take Antitumor Nanodrug as an Example

Navigating the complexities of cell death: Insights into accidental and programmed cell death

Emerging connectivity of programmed cell death pathways and its physiological implications